ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results
Lower commercial spending narrowed the quarterly loss, while ARS maintained its year-end 2027 cash flow breakeven expectation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ARS Pharmaceuticals (Nasdaq: SPRY) reported third-quarter 2026 revenue of $37.7 million, with higher neffy sales and a narrower net loss. U.S. neffy revenue reached $33.4 million versus $31.3 million a year earlier. Net loss narrowed to $35.6 million, or $0.36 per share, from $51.2 million, or $0.52 per share.
U.S. market share rose to 5% from 4%, while field-targeted accounts reached approximately 9% from 6%. Selling, general and administrative expenses fell to $43.5 million from $74.8 million. Research spending rose to $18.3 million, including a one-time intellectual-property license payment. Cash, cash equivalents and short-term investments totaled $138.4 million at September 30. ARS reaffirmed its expectation of cash flow breakeven by year-end 2027 under its current expense plan. Interim Phase 2b data for ARS-2 are expected in the first quarter of 2027, with full data later that year.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointQ3 neffy revenue increased to $33.414 million from $31.300 million a year earlier.
- Moderate pointQ3 net loss narrowed to $35.587 million, or $0.36 per share, from $51.151 million, or $0.52.
- Moderate pointQ3 selling, general and administrative expenses fell to $43.520 million from $74.751 million a year earlier.
- Moderate pointU.S. neffy market share reached 5% in Q3 2026, versus 4% in Q3 2025.
- Moderate pointQ3 unique prescribers reached 19,605, up 49% year over year; more than 44,000 have prescribed since launch.
- Moderate point. Forward-looking: it has not happened yet and may not happen.ARS-2 Phase 2b data are expected in Q1 2027 on an interim basis, with full data later in 2027.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Cash flow breakeven remains expected by year-end 2027, based on the company's current expense plan.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Second-half 2026 expense guidance remains $114 million–$126 million for combined commercial overhead and research, including stock compensation.
- Moderate pointNine-month revenue rose to $94.049 million from $56.191 million in the comparable 2025 period.
5 minor points
- Minor pointQ3 supply revenue rose to $2.635 million from $1.146 million a year earlier.
- Minor pointQ3 collaboration revenue increased to $1.661 million from $0.055 million a year earlier.
- Minor pointQ3 commercial overhead fell 42% from the first-half 2026 quarterly average.
- Minor pointField-targeted market share reached approximately 9%, versus 6% in Q3 2025; non-targeted accounts had 2%.
- Minor pointCommercial strategy is shifting toward account-based targeting, provider-focused messaging and an updated market access strategy.
Negative
- Moderate pointShort-term investments fell to $112.733 million at September 30, 2026, from $203.669 million at year-end 2025.
- Moderate pointStockholders' deficit reached $11.955 million at September 30, versus $114.258 million equity at year-end 2025.
- Moderate pointNet term loans increased to $121.807 million at September 30, from $96.374 million at year-end 2025.
- Moderate pointQ3 research and development expenses rose to $18.263 million from $2.751 million a year earlier.
- Moderate pointNine-month net loss widened to $158.544 million, or $1.59 per share, from $129.974 million, or $1.32.
- Moderate pointNine-month commercial overhead increased to $193.303 million from $170.167 million in the comparable 2025 period.
- Moderate pointNine-month cost of goods sold rose to $29.230 million from $14.269 million in the comparable 2025 period.
6 minor points
- Minor pointCash and cash equivalents fell to $25.621 million at September 30, 2026, from $41.317 million at year-end 2025.
- Minor pointFinancing liability increased to $75.208 million at September 30, from $72.140 million at year-end 2025.
- Minor pointQ3 cost of goods sold increased to $10.098 million from $8.191 million a year earlier.
- Minor pointQ3 interest expense rose to $2.552 million from $0.056 million a year earlier.
- Minor pointQ3 interest income declined to $1.136 million from $2.097 million a year earlier.
- Minor pointNine-month research expenses rose to $27.297 million from $9.738 million in the comparable 2025 period.
News Explained
At quarter-end, reported liabilities exceeded assets and the balance sheet showed stockholders’ deficit.
The third-quarter report records ARS Pharmaceuticals with 100,248,400 common shares issued and outstanding on
The same balance sheet lists total liabilities of
Key Figures
- Total revenue
- $37.7 million
- Q3 2026
- U.S. net product revenue
- $33.4 million
- neffy, Q3 2026
- U.S. market share
- 5%
- Q3 2026; compared with 4% in Q3 2025
- Field-targeted account market share
- 9%
- Q3 2026; compared with 6% in Q3 2025
- SG&A expense reduction
- 42%
- Q3 2026 versus the first-half 2026 quarterly average
- Net loss
- $35.6 million
- Q3 2026
- Cash, cash equivalents and short-term investments
- $138.4 million
- As of September 30, 2026
- Interim Phase 2b data
- First quarter of 2027
- ARS-2 trial
Previous Earnings Reports
-
Q2 revenue and neffy sales grew, while overall and field-targeted market shares advanced.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
phase 2b medical
chronic spontaneous urticaria medical
sg&a financial
stock-based compensation financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
Total Q3 revenue of
neffy U.S. market share reached
Reduced SG&A spend reflected in Q3 operating expenses; reaffirm path to cash flow breakeven by year-end 2027
Leadership team strengthened with appointments of Randall Kaye, M.D., as Chief Medical Officer and John Slebir as Chief Legal Officer
Conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT
SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals (Nasdaq: SPRY), a commercial biopharmaceutical company focused on needle-free epinephrine, today reported its financial results for the third quarter ended September 30, 2026, as well as recent corporate and commercial highlights.
“In August, we committed to three corporate priorities – steady market share gains with neffy, greater financial discipline with a path to cash flow breakeven by year-end 2027, and expansion of our needle-free epinephrine platform beyond anaphylaxis. I’m proud to report that our team has delivered on each,” said Donn Casale, President and Chief Executive Officer of ARS Pharma. “Market share grew where our field team engaged; operating expenses were in line with guidance, including a
“These results build the foundation for our future-looking three-pillar growth strategy – capture market share with neffy in our base market; expand the epinephrine market over time; and extend our platform, starting with our chronic spontaneous urticaria. With new leadership in place across our commercial, medical and legal functions, we have the team, the strategy and the discipline to execute. The opportunity in front of us is significant, and we believe we are well positioned to pursue it with focus and urgency.”
Third Quarter 2026 neffy Commercial Highlights
- Market share: Total U.S. market share reached
5% in the third quarter of 2026, up from4% in the third quarter of 2025. - Field-targeted market share: Market share among field-targeted accounts, which represent approximately
44% of the total market opportunity, reached approximately9% , up from6% for the same period in 2025. By comparison, market share was2% in non-targeted accounts in the third quarter of 2026. - Net U.S. product revenue: U.S. net product revenue for neffy of
$33.4 million , compared with$31.3 million in the third quarter of 2025. - Prescriber base: 19,605 total unique prescribers in the third quarter of 2026, up
49% compared with the third quarter of 2025, for a total of more than 44,000 prescribers since launch.
“neffy is a highly differentiated product in a large market with genuine demand, and I am confident it can become the standard of care in the epinephrine market,” said Meg Smith, Chief Commercial Officer. “The data show that when we engage providers directly, neffy wins. In my first two months, we completed a comprehensive assessment of our commercial operations, and we are taking decisive action across multiple fronts, including implementing a shift to account-based targeting, sharper provider-focused messaging, and a strengthened market access strategy. We are moving with urgency, and I expect the progress will continue to be reflected in our results, with steady gains over time.”
Business Updates
Leadership Appointments
ARS further strengthened its leadership team to execute its updated corporate and commercial strategy. In addition to the appointment of Meg Smith as Chief Commercial Officer in August 2026, the company also appointed:
- Randall Kaye, M.D., M.P.H, Chief Medical Officer (CMO). Dr. Kaye brings more than 30 years of experience in clinical development, medical affairs, and regulatory strategy. He has served as CMO at multiple biopharmaceutical companies, most recently at Longboard Pharmaceuticals, where he led clinical development of bexicaserin (LP352) and supported the company through its
$2.6 billion acquisition by Lundbeck in 2024. Earlier, as CMO of Avanir Pharmaceuticals, he designed and implemented the strategy that secured FDA approval of Nuedexta®. He began his industry career at Pfizer Inc., where he led late-stage clinical development of Zyrtec® and supported its U.S. launch. Dr. Kaye completed a fellowship in allergy and immunology at Harvard Medical School and a residency in pediatrics at the University of Massachusetts Medical School. He received his M.D. and M.P.H. from The George Washington University School of Medicine. - John Slebir, Chief Legal Officer and Corporate Secretary. Mr. Slebir brings more than 20 years of experience advising life sciences companies on commercialization, financings, strategic transactions, and governance. Most recently, he served as Senior Vice President, General Counsel, Corporate Secretary and Chief Trading and Compliance Officer at Dynavax Technologies, where he led legal support for the company’s
$2.2 billion acquisition by Sanofi in 2026. Previously, he spent more than a decade at VIVUS, Inc., including as Senior Vice President, General Counsel and Corporate Secretary.
Pipeline Expansion
ARS-2 is progressing in a Phase 2b trial evaluating 0.5 mg and 1.0 mg doses of needle-free epinephrine for the on-demand treatment of breakthrough flares in patients with chronic spontaneous urticaria (CSU). An estimated two million Americans live with CSU, and no FDA-approved therapy is indicated to stop an acute flare in progress. Interim data from the Phase 2b trial are expected in the first quarter of 2027, with full data later in 2027, which will inform the design of a potential Phase 3 registration program.
Third Quarter 2026 Financial Results
- Revenue: Total revenue for the third quarter of 2026 was
$37.7 million , consisting of U.S. net product revenue for neffy of$33.4 million , supply revenue of$2.6 million and collaboration revenue of$1.7 million . This compares with total revenue of$32.5 million for the third quarter of 2025, which included U.S. net product revenue of$31.3 million . - Total Operating Expenses: Third-quarter 2026 total operating expenses were
$71.9 million , including stock-based compensation of$8.1 million . Spending is tracking in line with second-half 2026 guidance of$114 million to$126 million in aggregate SG&A and R&D expenses, including stock-based compensation.- SG&A Expenses: Third-quarter 2026 SG&A expenses were
$43.5 million , compared with$74.8 million for the third quarter of 2025, primarily reflecting the discontinuation of linear TV and broad consumer advertising, along with more focused commercial investment. - R&D Expenses: Third-quarter 2026 R&D expenses were
$18.3 million , primarily related to a one-time$12.5 million payment related to a license agreement for exclusive worldwide rights to certain intellectual property, as well as advancing the Phase 2b trial of ARS-2 in breakthrough flares of CSU, compared with$2.8 million for the third quarter of 2025.
- SG&A Expenses: Third-quarter 2026 SG&A expenses were
- Net Loss: Net loss for the third quarter of 2026 was
$35.6 million , or$(0.36) per share, compared with a net loss of$51.2 million , or$(0.52) per share, for the third quarter of 2025. - Cash Position: As of September 30, 2026, ARS had cash, cash equivalents and short-term investments of
$138.4 million . Based on its current expense base plan, the company continues to expect to reach cash flow breakeven by the end of 2027.
Conference Call and Webcast
ARS will host a conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast will be available in the Investors & Media section of www.ars-pharma.com. Participants may register for dial-in access through the same page. A replay will be available for 30 days.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company developing and commercializing treatments that help at-risk patients and their caregivers treat and prevent severe allergic reactions. The company is commercializing neffy® (epinephrine nasal spray), the only needle-free epinephrine approved by the U.S. Food & Drug Administration, for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adults and children weighing 33 lbs. (15 kg) or more. In the European Union, the product is marketed as EURneffy®, the only needle-free epinephrine product authorized by the European Commission, for the emergency treatment of allergic reactions, including anaphylaxis, in adults and children four years of age and older weighing 15 kg or more. The product is also marketed as 优敏速® in China. Leveraging its intranasal technology, ARS Pharma is also developing ARS-2, currently in a Phase 2b clinical trial, as a potential first treatment for acute breakthrough flares of chronic spontaneous urticaria (CSU). For more information, visit www.ars-pharma.com and follow us on LinkedIn.
Forward-Looking Statements
Statements in this press release that are not purely historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: ARS Pharma’s updated strategic priorities and the anticipated benefits of their implementation, including a reduction in projected SG&A and R&D expenses for the second half of 2026 and expectations regarding operating expense trends into 2027; the anticipated path and timing to cash flow breakeven; the expected impact of the appointments of a new Chief Commercial Officer, Chief Medical Officer and Chief Legal Officer; the belief that neffy could become a standard of care; the expectation that the company’s shift to account-based targeting, provider-focused messaging and strengthened market access strategy will continue to be reflected in its results through steady gains over time; the anticipated timing for interim data from the urticaria trial and the potential for ARS Pharma’s intranasal epinephrine technology to expand into the urticaria indication; the expectation that realigning commercial investment toward targeted provider engagement will expand market share and support a durable growth trajectory for neffy; the potential for the CSU program to leverage existing commercial infrastructure and overlapping targeted prescribers and to represent a high-margin growth driver, if approved; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “anticipate,” “believe,” “can,” “expect,” “if,” “intend,” “may,” “on track,” “potential,” “plan,” “will,” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharma’s current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from neffy; the ability to maintain regulatory approval for neffy in its currently approved indications; the scope, progress and expansion of developing and commercializing neffy; the risk that personnel costs will be higher than anticipated; the scope, progress and expansion of developing our intranasal epinephrine technology; clinical trial results; the potential for governments and payors to delay, limit or deny coverage for neffy; the size and growth of the market for neffy and the rate and degree of market acceptance thereof vis-à-vis intramuscular injectable products; ARS Pharma’s ability to protect its intellectual property position; the adverse effects of pending litigation; and the impact of government laws, regulations and policies. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption 'Risk Factors' in ARS Pharma's Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, and as updated by the 'Risk Factors' in ARS Pharma's Quarterly Report on Form 10-Q for the quarter ended September 30, 2026. These documents are filed with the Securities and Exchange Commission and can also be accessed on ARS Pharma’s website at www.ars-pharma.com by clicking on the link “Financials & Filings” under the “Investors & Media” tab. The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharma assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Contacts
Investor Contact:
Monique Allaire, THRUST
monique@thrustsc.com
Media Contact:
Christy Curran, Sam Brown Inc.
christycurran@sambrown.com
| ARS Pharmaceuticals, Inc. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (in thousands, except par value and share amounts) | ||||||||
| September 30, 2026 | December 31, 2025 | |||||||
| (unaudited) | ||||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 25,621 | $ | 41,317 | ||||
| Short-term investments | 112,733 | 203,669 | ||||||
| Accounts receivable, net | 52,757 | 25,347 | ||||||
| Inventories | 11,711 | 8,369 | ||||||
| Prepaid expenses and other current assets | 8,206 | 6,194 | ||||||
| Total current assets | 211,028 | 284,896 | ||||||
| Inventories, noncurrent | 21,720 | 23,053 | ||||||
| Property, plant and equipment, net | 1,927 | 2,465 | ||||||
| Intangible assets, net | 13,624 | 14,452 | ||||||
| Other assets | 3,185 | 2,786 | ||||||
| Total assets | $ | 251,484 | $ | 327,652 | ||||
| Liabilities and stockholders’ (deficit) equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities (including related party amounts of | $ | 63,793 | $ | 37,948 | ||||
| Contract liability, current | 511 | 609 | ||||||
| Other current liabilities | 599 | 588 | ||||||
| Total current liabilities | 64,903 | 39,145 | ||||||
| Term loans, net (including related party amounts of | 121,807 | 96,374 | ||||||
| Financing liability | 75,208 | 72,140 | ||||||
| Contract liability, net of current portion | 1,047 | 1,130 | ||||||
| Other accrued liabilities | 474 | 4,605 | ||||||
| Total liabilities | 263,439 | 213,394 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ (deficit) equity | ||||||||
| Preferred stock, | — | — | ||||||
| Common stock, | 10 | 10 | ||||||
| Additional paid-in capital | 441,286 | 408,726 | ||||||
| Accumulated other comprehensive (loss) gain, net | (104 | ) | 125 | |||||
| Accumulated deficit | (453,147 | ) | (294,603 | ) | ||||
| Total stockholders’ (deficit) equity | (11,955 | ) | 114,258 | |||||
| Total liabilities and stockholders’ (deficit) equity | $ | 251,484 | $ | 327,652 | ||||
| ARS Pharmaceuticals, Inc. | ||||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| (unaudited) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Revenue: | ||||||||||||||||
| Product revenue, net | $ | 33,414 | $ | 31,300 | $ | 77,076 | $ | 51,863 | ||||||||
| Revenue under collaboration agreements | 1,661 | 55 | 4,207 | 2,859 | ||||||||||||
| Revenue under supply agreements | 2,635 | 1,146 | 12,766 | 1,469 | ||||||||||||
| Total revenue | 37,710 | 32,501 | 94,049 | 56,191 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Cost of goods sold (including related party amounts of | 10,098 | 8,191 | 29,230 | 14,269 | ||||||||||||
| Research and development (including related party amounts of | 18,263 | 2,751 | 27,297 | 9,738 | ||||||||||||
| Selling, general and administrative (including related party amounts of | 43,520 | 74,751 | 193,303 | 170,167 | ||||||||||||
| Total operating expenses | 71,881 | 85,693 | 249,830 | 194,174 | ||||||||||||
| Loss from operations | (34,171 | ) | (53,192 | ) | (155,781 | ) | (137,983 | ) | ||||||||
| Other income (expense), net: | ||||||||||||||||
| Interest income | 1,136 | 2,097 | 4,709 | 8,065 | ||||||||||||
| Interest expense (including related party amounts of | (2,552 | ) | (56 | ) | (7,472 | ) | (56 | ) | ||||||||
| Total other (expense) income, net | (1,416 | ) | 2,041 | (2,763 | ) | 8,009 | ||||||||||
| Net loss | $ | (35,587 | ) | $ | (51,151 | ) | (158,544 | ) | (129,974 | ) | ||||||
| Unrealized gains (losses) on available-for-sale securities | 36 | 39 | (229 | ) | (227 | ) | ||||||||||
| Comprehensive loss | $ | (35,551 | ) | $ | (51,112 | ) | $ | (158,773 | ) | $ | (130,201 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.36 | ) | $ | (0.52 | ) | $ | (1.59 | ) | $ | (1.32 | ) | ||||
| Weighted-average shares outstanding used in computing net loss per share, basic and diluted | 99,685,424 | 98,807,600 | 99,432,878 | 98,412,739 | ||||||||||||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were ARS Pharmaceuticals' third-quarter 2026 revenue and earnings?
ARS reported $37.7 million in revenue and a $35.6 million net loss, or $0.36 per share, for Q3 2026. A year earlier, revenue was $32.5 million and the net loss was $51.2 million, or $0.52 per share.
When does ARS Pharmaceuticals expect cash flow breakeven?
ARS continues to expect cash flow breakeven by the end of 2027, based on its current expense plan. Cash, cash equivalents and short-term investments totaled $138.4 million at September 30, 2026.
What is ARS Pharmaceuticals testing in the ARS-2 Phase 2b trial?
The trial evaluates 0.5 mg and 1.0 mg doses of needle-free epinephrine for on-demand treatment of breakthrough flares in chronic spontaneous urticaria, a condition involving recurring hives. The results will inform the design of a potential Phase 3 registration program.
Why did ARS Pharmaceuticals' research expenses increase in Q3 2026?
Research expenses primarily reflected a one-time $12.5 million payment under a license agreement for exclusive worldwide rights to certain intellectual property, alongside advancement of the ARS-2 Phase 2b trial. Quarterly research expenses were $18.3 million, compared with $2.8 million a year earlier.